Purdue Pharma Cuts More Than Half of U.S. Sales Staff Amid Opioid Crisis Post author:Sam Post published:February 12, 2018 Post category:BioPharma That announcement is a big change in the way Purdue has aggressively marketed OxyContin in the past. Source: BioSpace You Might Also Like Officials Eye New Biotech Tenants for Bristol-Myers' Former Connecticut Complex February 15, 2018 Jobs Affected as ImmunoGen Winds Down Ops at Massachusetts Facility February 13, 2018 Stock Plunges Despite Biohaven's Positive Migraine Data March 25, 2018